Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Open in API
Filings indexed 849 across all filing types
Latest filing 2019-06-27 Regulatory Filings
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
RW
Regulatory Filings Classification · 95% confidence The document is a letter from Histogenics Corporation to the SEC requesting withdrawal of a Registration Statement on Form S-3. It references the Securities Act and Rule 477, indicating a regulatory procedural filing. The document does not contain financial data, earnings, management discussion, or any report content. It is a formal regulatory communication about withdrawing a registration statement, which fits the category of Regulatory Filings (RNS). The document length is short and it is not a report itself but a regulatory notice.
2019-06-27 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes detailed information about a delisting notice from Nasdaq, a hearing panel decision to extend listing contingent on a merger, resignation of board members, and information about a proposed merger with Ocugen, Inc. It also references a proxy statement and solicitation materials related to the merger. The document is not a full annual or quarterly report, nor is it a transcript or earnings release. It is primarily an announcement of significant corporate events including delisting and management changes, as well as merger-related communications. The presence of director resignations and appointments points to Board/Management Information. The delisting notice and merger details also suggest a Delisting Announcement and M&A Activity, but since the document is a Form 8-K covering multiple events, the primary classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit neatly into other categories. The document is lengthy (15,000 characters) and contains substantive event disclosures rather than just a brief announcement or certification, so it is not an RPA or purely a certification. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2019-06-21 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes detailed information about a delisting notice from Nasdaq, a hearing panel decision to extend listing contingent on a merger, and changes in the board of directors. It also discusses the proposed merger with Ocugen, including references to proxy statements and registration statements to be filed. The document is not a full annual or quarterly report, nor is it a transcript or earnings release. It is primarily an announcement of significant corporate events including delisting and management changes, as well as merger-related disclosures. The presence of director resignations and appointments points to Board/Management Information. The delisting notice and related information about Nasdaq compliance and merger conditions indicate a Delisting Announcement. However, since the document is a Form 8-K current report covering multiple significant events including delisting and board changes, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit neatly into other categories. The document is detailed and substantive, not a brief announcement or certification, so RNS is appropriate rather than RPA or DEF 14A. Confidence is high due to the clear nature of the filing and content.
2019-06-21 English
S-4
Merger & Acquisition Classification · 100% confidence The document is a Form S-4 registration statement filed with the SEC, which is used for securities registration in connection with mergers and acquisitions. It includes detailed information about the merger agreement between Histogenics Corporation and Ocugen, Inc., the issuance of shares, voting matters, and related corporate actions. The presence of merger details, securities purchase agreements, and proxy statement/prospectus language indicates this is a filing related to a merger transaction. Form S-4 is specifically used for merger and acquisition filings. Therefore, the document fits the category of Merger & Acquisition filings (MA). The document length and content confirm it is the actual filing, not just an announcement or summary.
2019-06-14 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content details a merger agreement amendment and a securities purchase agreement related to financing activities. It includes specifics about the merger terms, financing shares, warrants, and conditions precedent to closing the merger and financing. This type of filing is not an annual or quarterly report, audit report, earnings release, or other financial statement. Instead, it is an update on capital and financing activities related to a merger transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2019-06-14 English
425 Filing
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a merger agreement amendment and a securities purchase agreement related to a merger transaction between Histogenics Corporation and Ocugen, Inc. It details terms of the merger, financing arrangements, and conditions precedent to closing. This is not a full annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing announcing material corporate events, specifically merger-related agreements and financing updates. The document is lengthy (15,000 characters) and contains detailed transaction information, consistent with a current report (8-K) filing. According to the classification definitions, this fits best under M&A Activity (TAR) because it involves merger proposals and takeover bid documents. Therefore, the filing type code is TAR with high confidence.
2019-06-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.